Follow-On Biologics Study By FTC Aims “To Strike The Right Balance”
FTC appears skeptical of generic exclusivity for biologics, but the approval procedure would prove a critical factor.
FTC appears skeptical of generic exclusivity for biologics, but the approval procedure would prove a critical factor.